Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug ...

The National Interest is an award-winning online publication focusing on defense issues, national security, military affairs and hardware, foreign policy, and U.S. politics. The National Interest ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function ...

The Chairman of National Sports Commission (NSC), Shehu Dikko, says the newly appointed management of the commission is in a race against time to develop sports in Nigeria. Dikko made the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Researchers from QIMR Berghofer Medical Research Institute in collaboration with Kazia Therapeutics have designed a drug called Paxalisib to combat metastatic triple negative breast cancer.

About Enalare Therapeutics Inc. Enalare Therapeutics Inc., is a clinical stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical ...

About Enalare Therapeutics Inc. Enalare Therapeutics Inc., is a clinical stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical ...

Current political and economic issues succinctly explained. President Donald Trump has repeatedly expressed his desire to regain U.S. ownership of the Panama Canal, which the United States ...